Plant extracts have long benefited from a simple image in the public imagination: a plant, an extraction, a product. In practice, access to the European and French markets has become far more technical. Today, it is no longer just the botanical origin or the tradition of use that counts, but also the measured concentrations, the tests carried out, the contaminants tested for, and the regulatory status. For both consumers and sellers, this evolution profoundly changes the way the sector is perceived.
In the European Union, as in France, the current logic is clear: access to plant extracts is based on "proof." Maximum levels, positive lists, pesticide residues, microbiological requirements, registration as a traditional herbal medicine, or classification as a food, supplement, or cosmetic: all of this is reshaping the market. For an adult consumer seeking legal, laboratory-tested, and compliant products, this framework is less of an obstacle than an essential quality filter.
A market for plant extracts increasingly structured by content
The major underlying trend in Europe is a shift from a fairly general approach to plants to a much more analytical approach to finished products and raw materials. In other words, the focus is no longer simply on which plant is used, but also on its exact composition, proportions, and safety standards. This is particularly evident in plant extracts intended for food, supplements, or wellness uses.
This transformation is based on a simple idea: two products derived from the same plant can have very different profiles depending on the variety, the part used, the extraction method, drying, storage, and even the final formulation. The EU-France framework therefore encourages operators to better document their sourcing, processes, and analyses. For buyers, this strengthens the appeal of products accompanied by clear laboratory results rather than mere marketing promises.
In this context, plant extracts are no longer freely available solely on the basis of their naturalness. They must fall into specific regulatory categories, meet measurable thresholds, and undergo increasingly stringent controls. This tightening of regulations does not prevent the market from moving forward; it primarily benefits those companies able to demonstrate the conformity, traceability, and stability of their products.
Infusions, hemp leaves and THC: the EU refines the thresholds
A recent and very telling example concerns hemp leaves intended for infusions. Regulation (EU) 2026/1828, adopted on 28 July 2026, amends Regulation (EU) 2023/915 to set maximum Δ9-THC levels applicable to hemp leaves used for water infusions as well as ready-to-drink infusions. Some levels will come into effect from 1 January 2027, thus allowing a period of adjustment for professionals.
This development is significant because it demonstrates that the European Union is no longer treating edible hemp as a vague category. It clearly distinguishes between different forms of consumption, in this case, infusions, and regulates the presence of a specific compound, Δ9-THC, through measurable limits. For reputable brands, this means moving beyond the "legal hemp" narrative and requiring analyses tailored to the actual product as it is sold and consumed.
For consumers, it's also a useful framework for understanding the product. When a plant-based product is presented for infusion, the key question isn't just its origin, but also its compliance with specific regulatory limits. This regulatory precision secures the market and enhances the value of tested products, particularly in sectors related to CBD where sensitivity to cannabinoid levels is naturally high.
“Herbal infusions” are becoming a separate category of control
Regulation (EU) 2023/915 provides another major clarification: it explicitly distinguishes between infusions made from flowers, leaves or herbs, roots, and other plant parts. This may seem highly technical, but this segmentation serves as the basis for contaminant and toxin controls. In short, Europe no longer considers herbal teas and infusions as a single, uniform category.
Why is this crucial for access to plant extracts ? Because a well-defined regulatory category then facilitates the setting of thresholds, control methods, and targeted obligations. A leaf, a flower, or a root does not necessarily accumulate the same contaminants or the same substances of interest. The framework therefore becomes more precise, but also more consistent with agronomic and industrial realities.
For professionals selling plant materials, extracts, or derived products, this level of detail necessitates increased vigilance regarding product classification. Incorrect categorization can lead to errors in required analyses, applicable thresholds, or labeling. Conversely, a thorough understanding of these distinctions allows for the development of a more robust and defensible product offering in the event of an inspection.
Residues, microbiology, contaminants: safety is at stake in the laboratory
The 2026 update on plant protection product residues confirms this trend. Regulation (EU) 2026/147 sets maximum residue levels for several substances and includes a specific provision for “teas, coffee, herbal infusions, cocoa and carobs”. This detail demonstrates how plant extracts and food plants are integrated into a very precise safety framework, with distinct requirements depending on the matrix.
In addition to these factors, there are microbiological issues. ANSES (the French Agency for Food, Environmental and Occupational Health & Safety) points out that microbial contaminants and decontamination treatments are major concerns for herbs and spices, and this also applies to many other plant-based raw materials. Drying, storage, residual moisture, and heat treatments directly influence the microbial load. A plant product can therefore be botanically excellent yet unsafe from a health perspective if it has been improperly prepared or stored.
For consumers, the implication is simple: a good plant extract isn't judged solely on its appearance or price. It's also essential to consider the tests and controls performed: residues, heavy metals, microbiology, specific contaminants, and even the composition profile. This is precisely where laboratory-tested products become truly valuable, especially for those seeking to combine affordability with genuine compliance.
Food, supplement, cosmetic or medicine: the status changes everything
The European framework clearly distinguishes between food, food supplements, cosmetics, and medicines. This separation is essential because the same plant extract can be subject to completely different regulations depending on its presentation, intended use, and purpose. The Commission reiterates that EU pharmaceutical legislation applies to traditional herbal medicines, while other uses fall under food or cosmetic regulations.
This point is often underestimated. Two products containing a similar plant base may not have the same market access pathway at all. If the product claims a therapeutic effect or falls within the scope of traditional herbal medicine, it becomes subject to much stricter registration and monitoring requirements. If it is presented as a food or supplement, other rules apply, particularly regarding contaminants, labeling, and safety.
In practice, regulatory status becomes a key factor in understanding why some extracts are easily marketed while others encounter obstacles. It's not necessarily the plant itself that's the problem, but rather how the product is formulated, presented, and justified. The market for plant extracts is therefore being reshaped less by botany alone than by the legal framework surrounding each use.
The pharmaceutical aspect: lists, registrations and well-established use
The European Union also revised the list of plant substances that can be used in traditional herbal medicines in 2026, through Implementing Decision (EU) 2026/334, which notably concerns Foeniculum vulgare. This update demonstrates that access to the pharmaceutical market for plant extracts depends on an evolving documentary framework, based on recognized preparations, identified uses, and defined forms.
In France, traditional herbal medicines must be registered. The Public Health Code penalizes the marketing of unregistered products, products whose registration has been refused, suspended, withdrawn, or has expired, with penalties of up to two years' imprisonment and a fine of €150,000. The message is clear: once a product falls under the pharmaceutical category, improvisation is no longer acceptable.
French authorities also emphasize the importance of well-established medical use, sometimes assessed over at least 10 years in France or the European Union. This tends to favor extracts with the best historical and scientific documentation. In other words, to access the market for therapeutic purposes, tradition alone is not enough: it must be structured, proven, and part of a recognized procedure.
France retains powerful national levers over medicinal plants
Beyond European law, France maintains a pharmaceutical monopoly on some medicinal plants listed in the pharmacopoeia. The Public Health Code restricts their sale to pharmacists, except for exemptions provided for by law. This national peculiarity continues to have a tangible impact on the distribution of many herbal products.
However, there are some openings. Article D. 4211-11 of the Public Health Code provides a list of medicinal plants or parts of plants that can be sold outside of pharmacies by non-pharmacists, in the manner specified in that list. This means that access to the French market depends not only on a general European status, but also on sometimes very specific national distribution rules.
France can also act quickly when a risk is identified. The decree of April 15, 2025, suspending the import, introduction, and marketing in France of food supplements containing Garcinia spp., is a good example. Even in a market harmonized at the European level, national authorities therefore retain significant room for maneuver, capable of suddenly restricting access to certain products.
Increasingly precise technical specifications for extracts
Plant extracts used as food additives are also subject to strict controls. Regulation (EU) 2025/2084 amended the specifications for quillaia extract (E 999), particularly regarding contaminant levels and microbiological criteria. This example is valuable because it shows that even when an extract is already recognized in the food industry, its market access remains subject to evolving technical requirements.
The logic of "contents" therefore does not only concern sensitive substances like THC. It also extends to impurities, processing residues, microbiological parameters, and the very composition of the extract. The more processed the product and the more it is intended for a structured food chain, the higher the level of documentation requirements.
For reputable brands, this evolution is demanding but positive. It favors supply chains capable of standardizing their processes, securing their batches, and providing legible certificates of analysis. For end consumers, it makes the market more mature: they can now compare not only price or aroma, but also a genuine level of compliance and reliability.
Why this framework is fundamentally reshaping access to plant extracts
Ultimately, the European and French movement is resulting in a natural selection of operators. Those who rely on traceability, laboratory testing, regulatory compliance, and solid documentation gain legitimacy. Those who rely on vague arguments about "natural" or "traditional" are more exposed to blockages, withdrawals, or sanctions. Access to plant extracts is therefore becoming more professional, more technical, and more verifiable.
This evolution is also changing the way we buy. For an adult consumer in France or Europe, the key question is no longer simply “what plant is it?”, but “which regulatory category does this product fall under, what analyses have been carried out, and what levels are guaranteed?” In the world of hemp, CBD, and next-generation cannabinoids, this expertise is even more crucial because it determines both practical legality and peace of mind when using these products.
In this sense, the EU-France framework doesn't close the door to plant extracts ; it redefines it. It prioritizes products capable of demonstrating their quality, safety, and proper regulatory compliance. For discerning consumers and market players alike, this "evidence-based" approach is not a mere administrative detail: it is now the cornerstone of market access.
The landscape of plant extracts is therefore entering a phase of accelerated maturation. THC levels in certain hemp infusions, residue limits, microbiological issues, food or pharmaceutical status, the partial monopoly on medicinal plants in France, mandatory registrations: all these elements form a coherent framework, even if it sometimes appears complex. This complexity has one major advantage: it is pushing the market towards greater clarity and control.
For adults seeking reliable plant-based products, particularly in the wellness hemp sector, this context reinforces the value of tested, traceable, and legally compliant products. By 2026 and beyond, access to plant extracts will no longer depend solely on storytelling, but on the ability to prove what a product contains, what it does not contain, and the precise framework within which it can be sold.
